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Despite significant recent advances in the applicability and outcome following unrelated 
cord blood transplantation (UCBT), infections remain a major cause of mortality asso-
ciated with poor immune recovery in the first 6 months after UCBT. Enhanced immune 
reconstitution not only could improve survival by reduced transplant related mortality, 
but may also favorably impact on relapse incidence by improved graft-versus-leukemia 
effects. This review will summarize our current understanding of the biology of immune 
recovery post-UCBT with an emphasis on adaptive T cell dependent immunity. New ef-
forts to boost immunity will be also highlighted including our own laboratory, where ex 
vivo T cell expansion is pursued towards adoptive immunotherapy.
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INTRODUCTION
  Bone marrow transplantation (BMT) has emerged over 
the past 50 years as a life-saving therapy for many human 
diseases. Although the first reports of successful trans-
plantation described children with inherited immune defi-
ciency disorders, one with severe combined immunodefi-
ciency (SCID) [1], and another with Wiskott-Aldrich syn-
drome (WAS) [2], most recipients of allogeneic hema-
topoietic stem cell transplant (HSCT) are adults and suffer 
from acquired disorders; leukemia, lymphoma, or aplastic 
anemia. Regardless of the underlying disease, from the begin-
ning of HSCT, it became apparent that adoptive transfer 
of healthy marrow and the progeny of donor bone marrow 
derived hematopoietic stem cells can lead to full recon-
stitution of the immune system. Among the most significant 
advances in HSCT over the past decades have been explora-
tions into the use of alternate hematopoietic grafts, to include 
allogeneic unrelated umbilical cord blood [3-5]. Cord blood 
(CB) is a by-product from childbirth that historically had 
been discarded. Experimental studies demonstrated that CB 
is enriched in primitive hematopoietic progenitors compared 
with adult bone marrow (BM) and mobilized peripheral 
blood stem cell grafts (PBSC), reviewed in [6]. Notably, 
long-term engrafting cells are almost eightfold enriched 
among CB CD34+ cells compared to those in CD34+ cells 
from PBSC. Moreover, CB-derived CD34+ progenitors dis-
play a ∼15-fold higher multilineage proliferative capacity 
[7]. These biological features could explain the unexpected 
clinical finding that despite a slower pace of myeloid engraft-
ment after CB transplantation there is a higher prevalence 
of early progenitors in the marrow space in those children 
who were given CB as opposed to BM transplant [8]. 
  CB as a hematopoietic graft was first used in 1989 for 
a child with severe Fanconi anemia [9]. Since 1993, when 
the first ever unrelated cord blood transplant (UCBT) was 
performed at Duke University [10], ＞20,000 such transplants 
are estimated to have been performed worldwide [11]. The 
increasing use of CB in the unrelated donor setting is partially 
explained by the following significant findings. UCBT appa-
rently offers a similar [12] or reduced risk [13] of severe Korean J Hematol 2010;45:224-35.
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graft-versus-host-disease (GVHD) permitting a less stringent 
criteria for HLA matching, reviewed in [14].
  Although UCBT is a life-saving form of HSCT, it is limited 
by the high incidence of opportunistic infections (OI), most 
of which are viral. OI is the major cause of transplant-related 
mortality during the first 6 months after UCBT, and is caused 
by delays in immune reconstitution. Immune reconstitution 
is a highly complex process influenced by both graft (e.g. 
cell dose, histocompatibility, donor serology) and recipi-
ent-related factors (age, previous therapy, conditioning regi-
men, past infectious exposures, etc). Adaptive immunity is 
the cumulative effect of a network of phenotypically distinct 
and highly specialized leukocyte subpopulations. Antigen 
presenting dendritic cell (DC), effector, memory, and regu-
latory lymphocyte subsets are the principal players of this 
network. Instructional signals from the innate immune sys-
tem shape the quality and net effect of antigen-specific 
immunity. 
  While attaining normal ranges of specific leukocyte subsets 
have been used extensively in the literature, protection from 
clinical infections is the best surrogate marker of successful 
immune reconstitution. 
THE HIGH INCIDENCE OF INFECTIONS AFTER 
UCBT OCCURS PREDOMINANTLY WITHIN 
THE FIRST 3-4 MONTHS AFTER TRANSPLANT
  Infection-related mortality (IRM) is the primary or secon-
dary cause of death (with or without another major cause 
such as GVHD) in ≥50% of deaths after UCBT with the 
majority of them occurring in the first 100 days [14-17]. 
A classic report from the International Bone Marrow 
Transplant Registry (IBMTR) highlights the unique features 
of infection incidence after UCBT. Outcome after trans-
plantation was analyzed between recipients of either CB 
(N=150) or from marrow that was from HLA-matched (N= 
367) or mismatched for 1 HLA antigen (N=83) [18]. IRM 
within 100 days after transplantation was significantly higher 
among recipients of mismatched CB than among recipients 
of either HLA-matched marrow or mismatched marrow 
(45%, 21%, and 24%, respectively; P=0.01). However, be-
yond day 100, the proportions of infection-related deaths 
were similar in the 3 groups. A multicenter study from Spain 
also found increased occurrence of severe infections during 
the first 100 days after UCBT (73%) than in the BMT/PBSC 
groups (50%; P=0.02) [19]. Similarly, the Minnesota group 
also documented higher cumulative incidence of serious in-
fections among children receiving UCBT (58%) immediately 
post-transplant in contrast to recipients of unmanipulated 
BM (35%, P=0.04) [20]. However, subsequently there was 
a trend towards less serious infection in the UCBT group 
similar to the findings of IBMTR report [18], suggesting 
that the immune deficit that seems to be so heightened 
in the immediate post-UCBT period is followed by significant 
improvements of immunity. Although causal relationship 
cannot be established directly, this period coincides with 
the time of thymic recovery. When the Minnesota group 
analyzed 2 BMT cohorts separately, patients in the T cell-de-
pleted group demonstrated significantly more viral (P
＜0.01), but not bacterial, infections than either UCBT or 
unmodified BM recipients beyond 6 months. These findings 
together with the report by the COBLT investigators [21] 
suggest an important protective role for post-thymic T cells 
infused in the graft regardless whether they include antigen 
experienced (marrow) or almost exclusively antigen naïve 
(CB) T cells. 
GENERAL PRINCIPLES OF IMMUNE 
RECOVERY AFTER HCT
  Immunoablation is an obligatory consequence of most 
myeloablative preparative regimens. While as a whole the 
innate immune system appears to recover rapidly, within 
weeks after HCT, the recovery of functional B and T lympho-
cytes (adaptive immunity) is far more difficult to achieve 
[22, 23]. The first wave of T cells emerging in the lympho-
penic host are peripherally expanding T lymphocytes that 
were infused with the graft representing the thymic-in-
dependent pathway [24]. However, the antigen-driven ex-
pansion of peripheral T cells leads to a limited and skewed 
T cell receptor (TCR) repertoire [24]. Several weeks/months 
later a second wave of T cells emerge developing from do-
nor-derived common lymphocyte progenitors (CLP) as the 
result of de novo thymopoiesis. In the absence of significant 
GVHD, this thymic-dependent pathway [25, 26] is solely 
responsible for a fully diverse T cell repertoire. Interestingly, 
by 2 years after HCT higher TCR diversity may be attained 
in CB recipients than in recipients of BMT [27] indicating 
the existence of an efficient thymic-dependent pathway.
PLACENTAL FACTORS SHAPE THE FUNCTIONAL 
PROFILE OF FETAL T CELLS AND DENDRITIC 
CELLS RESULTING IN FUNCTIONAL DEFICITS 
  CB contains significantly higher absolute numbers of T, 
NK, and B lymphocytes than adult peripheral blood (PB) 
or even marrow [28-31]. However, functional differences 
are more critical compared to numerical ones. Despite an 
overlapping CD45RA
+/CD28
+/CD27
+ phenotype, CB T cells 
are fundamentally different from ‘naïve’ adult T cells mostly 
because they demonstrate a relative Th2/Tc2 bias. Multiple 
tiers of Th1/Tc1 suppressing factors exist at the maternal-fetal 
interface; IL-10 secreted by cytotrophoblasts [32], reduced 
local Tryptophan levels [33], increased progesterone levels 
[34] and other placental factors (IL-4, PGE2), reviewed in 
[35]. This immunoregulatory network could be viewed as 
part of an evolutionary adaptation to permit survival and 
avoid rejection of the fetus. Fas-ligand expression at the 
maternal-fetal interface may eliminate T cells activated de-
spite these factors above [36]. The exuberant production 
of IL-13 primarily by CD8
+ T cells [37] is in sharp contrast Korean J Hematol 2010;45:224-35.
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with lower IFNγ production that persists even after stim-
ulation via CD3/CD28 signaling and exogenous IL-2 [37]. 
This is a consequence of differential patterns of methylation 
of the IFNγ promoter [38]. Independently, impaired APC 
function of neonatal/CB dendritic cells (DC) restricts the 
potential for optimal Th1 cell responses in neonates due 
to their low IL-12 expression [39-41]. Despite these limits, 
there is evidence that intrauterine viral infections (e.g. cyto-
megalovirus, CMV) could generate partial Th1 immune re-
sponses [35], though persistent and selective deficiency of 
antiviral Th1 CD4
+ T cell is documented into early childhood 
[42]. The reduced capacity of bulk CB mononuclear cells 
to secrete cytokines and lymphokines has been reported 
to affect GM-CSF, M-CSF, IL-4, IL-8, IL-12, IL-15, and IL-18, 
reviewed in [43, 44]. There is reduced expression of NFATc2 
(nuclear factor of activated T cells c2), a critical transcription 
factor necessary for up-regulation of these and other cyto-
kines known to amplify T-cell responses. The relative cyto-
lytic deficiency of CB T cells is associated with absent ex-
pression of granzymes and perforin [45], essential for the 
control of viral and other pathogens. Nevertheless, as 
Kyung-Duk Park in my laboratory demonstrated [46], in 
vitro priming against CMV is feasible, if Th1/Tc1 skewing 
cytokines influence CB T cells before and during antigen 
encounter. CD25
＋ T cells in CB are naturally-occurring regu-
latory T cells [47] with potent suppressor function as opposed 
to peripherally activated CD25
+ cells [48]. Fewer UCB T 
cells display HLA-DR and CCR-5 activation markers, while 
the CD8
＋/CD57
＋/CD28
− and CD8
＋/CD45RA
＋/CD27
− ‘cytotoxic’, 
along with the ‘skin homing’ CLA+ T cell subsets are absent 
altogether [30]. Compared with adult blood more CB T cells 
progress through cell cycle and enter apoptosis. However, 
unlike in adult PB the majority of proliferating Ki-67+ T 
cells in UCB retain a CD45RA
＋/RO
−, CD69
−, CD25
−, HLA
− 
DR
− ‘resting’ phenotype [30, 49]. Unlike in adult blood, 
there is also significant expression of telomerase in CB T 
cells [49]. In contrast with T cells, CB NK cells are function-
ally “mature” with comparable or better lytic activity than 
their BM-derived counterparts [50]. Not surprisingly, ‘naïve’ 
B lymphocytes are in excess in CB with an abundance of 
CD5
＋ B1 cells and CD23
− immature B cells [30, 51].
PREVIOUSLY REPORTED FEATURES OF 
IMMUNE RECOVERY AFTER UCBT 
  Although mitogenic proliferative responses may already 
reach normal range in children 6-9 months after UCBT, 
T cell reconstitution is gradual and typically does not reach 
age-appropriate numbers before 9 months. Meanwhile, T 
cell recovery in adults typically extends beyond the first 
year, presumably related to the inferior output of TREC+ 
naïve T cells in older recipients [52]. Notably, NK cell recov-
ery is prompt both in numbers and function in both adults 
and children by the first 2 months similar to recipients of 
BM [53-55]. Significant B lymphocyte recovery starts ∼2- 
4 months after transplant and according to a recent analysis 
of a combined dataset from Marseille and Lyon, they may 
recover relatively fast, by ∼3 months after CBT compared 
to  ∼6 months post-unrelated donor BMT [55]. 
  Although the incidence of life-threatening viral infections 
is high in the first 6 months after UCBT likely reflecting 
deficits in T cell numbers or function, when monitored be-
yond 9 months post-transplant the speed of T cell recovery 
seems to be at least comparable [56] to or even better than 
that seen after unrelated BMT, [31, 53, 57]. Investigators 
from the Cord Blood Transplantation Study (COBLT) ana-
lyzed antigen-specific proliferation after UCBT [21]. Child-
ren with malignancies were longitudinally tested over the 
first 3 years post transplant for herpes virus specific responses 
(HSV, VZV, CMV). Approximately 43% of the patients stud-
ied eventually developed a positive T-lymphocyte pro-
liferative response to at least one herpes virus at some point 
over the 3 year observational period. In a few, proliferative 
responses developed as early as within the first 30-50 days, 
indicating that naïve T lymphocytes transferred in the graft 
can give rise to antigen-specific T-lymphocyte immunity 
before thymic recovery [21]. Surprisingly, patients with a 
proliferative response at any time in the first 3 years to 
any of the herpes viruses had a lower probability of leukemia 
relapse and a higher overall survival [21]. One may speculate 
that the superior proliferative T cell response represents 
a powerful surrogate marker for functional immune recon-
stitution leading to more effective graft-versus-leukemia 
(GVL) activity. However, the development and kinetics of 
protective antigen-specific function was not evaluable [58]. 
    Investigators at the University of Minnesota retro-
spectively evaluated the impact of overall lymphocyte recov-
ery in 360 consecutive patients with hematologic malignancy 
utilizing data from standard hemocytometers [59]. Patients 
underwent UCBT between 2001 and 2007. In multivariate 
analysis, an absolute lymphocyte count (ALC) of ＞200× 
10
6/L at day 30 (N=73) after myeloablative conditioning was 
associated with superior 2-year overall survival (OS) (73% 
vs. 61%; P=0.02), progression-free survival (PFS) (68% vs. 
54%;  P=0.05) and reduced transplant related mortality 
(TRM) (8% vs. 28%, P＜0.01) compared to those whose 
ALC was ≤ 200×10
6/L (N=43). Similarly, an ALC＞200× 
10
6/L at day 42 (N=105) after RIC was associated with superior 
2-year OS (59% vs. 41%, P＜0.01) compared to those below 
(N=55). There was no significant relationship between ALC 
and relapse [59].
PATIENT AND GRAFT SPECIFIC FACTORS PREDICT 
THE RISK OF DEATH FROM OPPORTUNISTIC 
INFECTIONS IN THE FIRST 6 MONTHS AFTER UCBT 
  Over the past several years the Szabolcs lab has studied 
the reconstitution of immunity in the immediate post-UCBT 
period (prior to thymic recovery) in ＞150 pediatric recipi-
ents of single unit UCB at Duke University to identify surro-
gate immune markers for those at risk for opportunistic 
infections (OI).Korean J Hematol 2010;45:224-35.
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Table 1. Continuous variables of immunity associated with OI 
incidence in the first 100 days. Measurements in the ‘Day +50 
study’ group.
Variable
Median 
value for 
patients
with OI
Median value
for patients
without OI
Logistic
regression 
(P)
Abs No. CD4
＋
T Cells (cell No. /μL)
44 137 0.02 without age
in model
% CD8
+ T Cells 44 14 ＜0.0001
% CD57
+/CD28
−/
CD8
＋ T cells
93 ＜0.02
% CD25
＋/CD3
＋
T Cells
22 40 ＜0.016
% TCRγδ T cell subset 2.3 0.97 ＜0.017
% ‘activated’ 
HLA-DR
＋ T cells
53 38 ＜0.009
% ‘NKT’ CD3
＋/
CD56
＋ T cells
84 ＜0.01
% IFNγ secreting 
T cells
18 4 ＜0.006
Confounders tested: Race, age, gender, weight, CMV status, HLA 
mismatch, malignancy, TBI, GVHD, High Dose steroid pulse (yes, 
no), Anti-CD25/Daclizumab pulse (yes, no), infused total cell 
dose/kg, CD34+cell/kg, CD3+ T cell dose/kg.
Fig. 1. Kaplan-Meier curve of survival (months) after UCBT in 330 
consecutive patients. Death related to opportunistic infections (OI ) is
the major cause of failure, most occurring by 6 months. Reproduced 
with permission from Cytotherapy  Ⓒ  2007, Informa Healthcare 
Journals.
  Several graft and patient-specific variables were identified 
as significant factors, when the laboratory measurements 
of DC and T cell reconstitution were analyzed. To determine 
the impact of patient and graft-specific factors on 6-month 
post-UCBT OI-related mortality, we reviewed all consecutive 
pediatric UCB recipients transplanted at Duke University 
Medical Center between June 1999 and Oct 2005 to overlap 
with the immune monitoring studies [60]. Three hundred 
thirty pediatric recipients of single UCB grafts were 
identified. Those receiving a second transplant for primary 
graft failure were excluded. Two hundred twenty of the 
330 patients (67%) were alive at 6 months (Fig. 1). Of those 
who died by 6 months, 58% were identified with OI (viral, 
fungal, protozoal infections) implicated as a cause of death. 
Those who died prior to 6 months and for whom OI was 
not implicated as a cause of death were omitted from the 
study dataset, resulting in 284 patients. 
  Multivariate modeling revealed that a significantly greater 
probability of 6-month OI-related death was associated with 
CMV-positive serology, greater HLA mismatch, and older 
age. Higher total graft cell dose, including CD34
＋ progenitor 
cell dose and CD3
＋ c e l l  d o s e  w e r e  e a c h  a s s o c i a t e d  w i t h  
lower probability of death due to OI at 6 months [61]. Here 
we demonstrated for the first time the protective immunity 
afforded by expansion and functional contribution of 
post-thymic T cells infused with the graft prior to the recov-
ery of the “central” de novo thymic pathway. We are in 
the midst of analysis of longitudinal monitoring of dendritic 
cell and lymphocyte recovery during the first 2 years after 
UCBT with emerging protecting influence of Tregs in the 
first 6 months coupled with the protective effects of thymus 
regeneration at the 6 months time point and CD123+ plasma-
cytoid dendritic cell recovery, data not shown.
CIRCULATING DENDRITIC AND T CELL SUBSETS 
AT DAY +50 AFTER UCBT SERVE AS SURROGATE 
MARKERS OF PROTECTIVE IMMUNITY 
  To identify patients who were at increased risk for develop-
ing OI in the first 100 days, a prospective cross-sectional 
study has been conducted at day +50 post-UCBT [62], with 
the latest analysis extended to 111 patients. Utilizing 
Trucount
TM methodology, 4-color surface and intracellular 
(ic) FACS was employed to accurately enumerate and charac-
terize lymphocyte and DC subsets [30, 63, 64]. All patients 
received myeloablative conditioning regimes (TBI/CY, 
Bu/CY, Bu/MEL, TBI/MEL) and equine ATG at 30 mg/kg/day 
between day −3 to day −1. All received identical GVHD 
prophylaxis consisting of Cyclosporine A plus steroids, slowly 
tapered after day +21 in the absence of ≥grade II aGVHD. 
Various degree of cellular reconstitution is noted for most 
immune cells except for the absence of B lymphocytes. 
However, immune reconstitution varied widely. 
  Table 1 lists those immune parameters that remain sig-
nificant predictors for the presence of de novo developed 
OI. Fig. 2 shows that individuals that develop OI by day 
+100 have a significantly reduced probability of overall sur-
vival (Fig. 2A) and that death due to OI is related to Grade 
III/IV GVHD (Fig. 2B). Based on these data [62], and also 
on data not shown, we hypothesize that the increased preva-
lence of CD8+ T cells expressing/secreting HLA-DR, IFN, 
Granzymes A, B, Perforin represent an effort by the emerging 
immune system to control the infectious agent. These Korean J Hematol 2010;45:224-35.
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Fig. 2. (A) Time to death from all causes in the “Day 50” cohort by opportunistic infection status. (B) Time to death from OI by presence or absence
of severe GVHD. Reproduced with permission from Cytotherapy Ⓒ 2007, Informa Healthcare Journals.
changes accompany down regulation of CD28 and CD27 
expressions along with CD57 upregulation thus represent 
an evolution towards effector phenotype and function. Along 
with the skewing of the T cell profile, significantly fewer 
CD123
＋ plasmacytoid/lymphoid DC circulate in those with 
infection (P=0.007) demonstrating that antigen-presenting 
cell deficiency occurs along with lymphocyte alterations.
TH1 AND TC1 T CELL SUBSETS MEASURED 
AT DAY +20 AFTER UCBT CAN PREDICT 
THOSE AT RISK FOR OI
  With another study we aimed to gain insight into the 
fate and maturational biology of adoptively transferred naive 
T cells in the lymphopenic hosts even prior to the onset 
of OI to develop predictive models for OI incidence in the 
first 100 days. Blood was obtained at a median 18 days 
post-UCBT if the WBC exceeded 400/mm
3. Circulating T-cell 
subsets and DC counts were monitored. Since our last report 
[65], we have analyzed 76 patients at a median age of 62 
months with at least 12 months follow-up. Forty four patients 
(58%) presented de novo with OI (＞90% viral) at a median 
of 35 days. Both the OI+ and OI- patient cohorts had low 
but equivalent absolute WBC, CD3
＋, CD4
＋ T cells, and NK 
lymphocytes. DC subsets were largely undetectable. Strikingly, 
∼40% of circulating T cells were proliferating (Ki-67
＋), 
regardless of OI status, reflecting vigorous peripheral ex-
pansion reducing the CD45RA
＋/CD62L
＋ RTE pool to ＜20% 
from  ＞90% infused in the graft only 2-3 weeks earlier 
[30]. While most cells (67±27%) expressed a ‘memory like’ 
CD45RA
−/CD45RO
＋ phenotype, a significant population 
(14±28%) co-expressed CD45RA and RO. The robust T cell 
expansion was accompanied by upregulation of markers of 
activation with a median of 66% of T cells HLA-DR
＋. 
Interestingly, ∼10% of the circulating T cells were entering 
apoptosis (ic activated Caspase-3+), regardless of OI status. 
  In those who developed OI, significantly higher proportion 
of the circulating T cells were CD8
＋ (40% vs. 28%, P=0.04), 
expressed CCR-5 (82% vs. 55%, P=0.009), were secreting 
IFN (35% vs. 12%, P=0.01), and acquired a CD57
＋/CD28
− 
‘ e f f e c t o r  C T L ’  p h e n o t y p e .  I n  p a t i e n t s  d e v e l o p i n g  O I  s i g -
nificantly more Perforin
＋/CD8
＋ T cells circulated (48% vs. 
26%,  P=0.02).
  In conclusion, in the immediate post-transplant lympho-
penic period extensive T cell proliferation via peripheral 
expansion leads to major immunophenotypic alterations ac-
companied by a gradual loss of the original naïve phenotype. 
In parallel, new T cell subsets emerge displaying a phenotype 
associated with antigenic stimulation [66]. We hypothesize 
that in patients who will develop OI, even clinically un-
detectable levels of virus could induce phenotypic acquisition 
of Th1/Tc1 cytotoxic effector profile. 
CORD BLOOD T CELL EXPANSION IN VITRO 
WITH TH1 TC1 MATURATION; PRECLINICAL 
RESEARCH TOWARDS ADOPTIVE T CELL 
IMMUNOTHERAPY
  Recently, we and others have demonstrated the feasibility 
of ex vivo CB T cell expansion [67, 68], drawing from the 
pioneering work by June et al. [69] utilizing paramagnetic 
Dynal beads coated with anti-CD3 and anti-CD28 stim-
ulatory antibodies. These artificial antigen presenting cells 
(APC) simultaneously provide agonistic TCR and co-stim-
ulatory signals triggering sufficient T cell proliferation in 
vitro to generate clinically relevant DLI products from living 
donors [70-72]. Although in our previous work [67], robust 
T cell expansion and even partial Th1/Tc1 maturation was 
evident starting with frozen/thawed CB specimens, sig-
nificant apoptosis (∼16%) resulted in an inverted CD4/CD8 
ratio and diminished yield despite relatively low concen-
trations of IL-2 in the medium. The high degree of apoptosis Korean J Hematol 2010;45:224-35.
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Fig. 3. (A) CD3
+ T cell expansion is superior in the presence of IL-7. Frozen/thawed cord blood T cells were enriched by negative selection then split 
equally into two under identical culture conditions except for the presence of IL-7 as indicated. Cells were cultured for 12-14 days with ClinExVivo
TM
Dynabeads
Ⓡ, while medium and cytokines were replenished ×3/week. A 50 μL aliquot was removed from the bags at indicated time points and 
absolute T cells number was enumerated in Trucount
Ⓡ tubes. (B) Irrespective of IL-7 in the culture medium, expansion leads to dilution and near
complete loss of sjTREC in day 14 progeny. The signal joint TCR excision circles (sjTREC) were measured before and after expansion (N=4). For each
sample total nucleated cell count and absolute T cells content was enumerated by Trucount FACS method. TREC content was expressed after 
adjustment for 10
5 T cells/sample. Reproduced with permission from Cancer Research Ⓒ 2010.
was likely the result of activation induced cell death (AICD) 
following strong TCR signaling on CB T cells as previously 
described [73]. Infusion of overstimulated, apoptosis prone 
DLI product would likely lead to a narrow T cell repertoire 
and shortened T cell survival in vivo. Moreover, it could 
falsely suggest futility of ex vivo expanded DLI strategies. 
  In the most current study [74], we tested and confirmed 
our hypotheses, that interleukin-7 (IL-7) acting in concert 
with a new, clinical grade CD3/CD28 costimulatory bead 
and IL-2, would not only enhance ex vivo CB T cell pro-
liferation while retaining a broad TCR repertoire as predicted 
[75], but it would also reduce activation induced cell death 
(AICD). 
FAVORABLE IMPACT OF IL-7 ON CB T CELL 
SURVIVAL, PROLIFERATION, AND TCR V 
REPERTOIRE DURING CD3/28 
MEDIATED EXPANSION
  Purified T cells obtained from frozen/thawed cord blood 
specimens were split and cultured in parallel with and with-
out IL-7. Matched pair analysis demonstrated significantly 
mo re  v iab le  T c el ls  wh en  IL-7 was ad d ed  t o  IL-2 in t h e  
medium leading to an average of 165 fold T cell expansion 
(Fig. 3A). Following 14 days of expansion, striking dilution 
of TCR excision circles was noted as the sjTREC content 
in CD3+ T cells was depleted by ∼2 l o g  i n  b o t h  c u l t u r e  
conditions as compared to the starting population of pre-ex-
pansion CB T cells (Fig. 3B), irrespective of IL-7 exposure. 
Significantly more viable CD45 bright T lymphocytes were 
identified in cultures supplanted with IL-7 (71±10%) com-
pared to cultures with IL-2 alone (46±15%) As determined 
by ic activated Caspase-3 expression and 7-AAD staining, 
there were significantly fewer T cells undergoing active 
apoptosis in the presence of IL-7 (median 4% versus 8%) 
(Fig. 4B). The anti-apoptotic effect of IL-7 was evident in 
both CD4+ and CD8+ subsets. To test T cell survival promot-
ing effects of IL-7 beyond the in vitro expansion period, 
expanded cells were frozen on Day 14 and subsequently 
thawed and rested for 24 h in culture medium devoid of 
cytokines. Although the rest period in vitro can not mimic 
the in vivo post-infusion conditions exactly, these experi-
ments demonstrate that T cells post expansion retain the 
potential to up-regulate IL-7 receptor/CD127 (Fig. 4A), and 
that the majority of IL-7 + IL-2 expanded T cells are still 
alive after freeze, thaw, and 24 hour culture in medium 
(Fig. 5B). Independent of the described anti-apoptotic effects, 
IL-7 promoted significantly greater T cell proliferation. 
About 2/3
rd of all T cells were still actively cycling at the 
termination of the expansion period, as detected by intra-
cellular Ki-67 expression (Fig. 5). Since naïve T cells with 
recent thymic emigrant phenotype (CD28+/CD27+CD45RA+/ 
CD62L+) represent the vast majority of unmanipulated CB 
T cells, these findings corroborate earlier studies demonstrat-
ing the proliferative and anti-apoptotic effects of IL-7 to 
be operational predominantly in the naïve/CD45RA+ T cell 
compartment [75, 76]. In addition to superior T cell pro-
liferation and reduced apoptosis in IL-7 supplanted con-
ditions, we also found higher TCRVβ diversity per family 
(P=0.04, N=3) displaying a broad polyclonal spectrum [74] 
(data not shown).Korean J Hematol 2010;45:224-35.
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Fig. 4. (A) Kinetic analysis of surface CD25 and CD127 expression. Simultaneous monitoring of IL-2Rα (CD25) and IL-7Rα (CD127) was performed
after FACS surface staining and acquisition as described [30, 64] on serial aliquots obtained before (Day 0) and during expansion on the indicated
days. (B) Cell death after 24 h of rest in cytokine free medium was assayed and scored by positive staining for Annexin and 7-AAD in parallel after
freeze and thaw of expanded day 14 T cells, representative of 4 experiments. Reproduced with permission from Cancer Research Ⓒ 2010.
Fig. 5. Flow cytometry profile of the expanded T cell progeny±IL-7. Surface and intracellular (ic) FACS characterization was performed as shown
previously [30, 64, 67]. The relative size of T cell subsets in each quadrant is expressed as the percentage of total viable T cells, see Table 1 for 
P-values. (A) CD45-PERCP/SSC defines an unambiguous region of viable cells. All other CD45 dim cells (recently apoptotic) stain also dim for CD3,
data not shown. (B) icKI-67 staining (upper quads) identifies more proliferating T cells when expanded with IL-7 than without. (C) When expanded
without IL-7 more T cells undergo apoptosis and stain with ic ActiveCasp-3
+ even though gated from the viable region of Fig. 2A. (D) More T cells
display the phenotype of naïve/CD45RA
＋ /RO
− T cells when expanded with IL-7. Representative of 10 experiments. Reproduced with permission 
from Cancer Research Ⓒ 2010.
LIMITED TH1/TC1 ‘MATURATION’ DURING 
EXPANSION AND LOW EXPRESSION LEVELS OF 
4-1BB/CD137, CD40L, AND PERFORIN CORRELATE 
WITH ABSENT ALLOREACTIVITY
  Once we have demonstrated the salutary effects of IL-7 
on T cell viability, expansion, and overall T cell receptor 
diversity, we sought to determine its impact on surface and 
intracellular phenotype and overall T cell function as meas-
ured by cytokine secretion profile and cytotoxicity. Despite 
undergoing several cycles of cell division triggered by IL-2 
+IL-7 in concert with TCR and CD28 co-stimulation, sig-
nificantly more CB T cells retained the naïve starting pheno-
type, CD45RA+/CD62L+ in the IL-7-containing condition 
(90±5%) compared to cells cultured in IL-2 alone (73±14%, 
P=0.03) (Fig. 5). Surface expression of L-selectin (CD62L) 
is essential for effective T cell homing to secondary lymphoid Korean J Hematol 2010;45:224-35.
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Fig. 6. Absent cytotoxicity of the expanded CB T cells against allogeneic
targets irrespective of±IL-7. Effector T cells were obtained from PBL of
healthy volunteers as positive controls and compared with CD3/28 
co-stimulated CB T cells±IL-7. First, effectors were primed/sensitized 
against a highly immunogeneic (HLA-DR+, CD40+, CD80+, CD86+)
IM9 cell line for 7-9 days at 1：1 to 1：3 responder : stimulator ratio, 
then re-exposed to fresh BATDA
Ⓡ-loaded IM9 targets at the indicated
E：T ratios for 2 & 3 h. Europium release was measured by the Delfia
Ⓡ
EuTDA cytotoxicity assay [67] and the calculated percent specific 
cytotoxicity is presented on the Y-axis. Representative of 7 experi-
ments.
Fig. 7. Leukemia-specific CTL can be in vitro primed starting with the CD3/28-expanded CB T cells. T cells were first CD3/28-expanded in the 
presence of IL2+ IL-7 over 14 days as described and thereafter were primed/sensitized against 2 killed leukemia cell lines in parallel cultures for 7-9
days at 10：1 responder : stimulator ratio in the presence of IL-12, IL-7, and IL-15. (A) CTL primed in vitro with Mitomycin C-treated IM9 cells. (B)
CTL primed in vitro with IFN-treated and Mitomycin C-treated U937 cells. Each CTL culture was re-stimulated 2 more times (1
st IL7+ IL-15, 
thereafter 2
nd in IL15 alone) for a total of 3 weeks with their respective killed leukemia cells. Cytotoxicity of washed effectors after 3 weeks in CTL
culture was tested against fresh, unmodified, BATDA
Ⓡ-loaded IM9 (▲), U937 (■) cells, and recipient PHA blasts (◆) at the indicated E：T ratios
for 3 h, as indicated. Europium release was measured by the Delfia
Ⓡ EuTDA cytotoxicity assay, and the calculated percent specific cytotoxicity is
presented on the Y-axis. Reproduced with permission from Cancer Research Ⓒ 2010.
organs, a desired destination for antigen inexperienced, un-
primed adoptive T cell infusions. CCR-7, a chemokine re-
ceptor implicated in both the entry and also in the retaining 
of T cells in lymph nodes, was also expressed on the majority 
of expanded T cells, data not shown. Interestingly, while 
the surface of post-expansion T cells appeared identical to 
unmanipulated fresh cord blood T cells in terms of CD28+/ 
CD27+/CD45RA+/CD62L co-expression, expanded T cells 
displayed several upregulated surface molecules commonly 
seen after activation, including CD25, HLA-DR, OX40. 
However, ＜10% of cells expressed CD40L. Despite the pres-
ervation of resting, naïve, ‘RTE-mimicking’ surface pheno-
type, as indicated by CD28+/CD27+/CD45RA+/CD62L co-ex-
pression, CD3/CD28 co-stimulation led to rapid down-regu-
lation of membrane CD127 (IL7Rα) in parallel with surface 
CD25 (IL2Rα) up-regulation on the very same T cells (Fig. 
4A). This ‘receptor switching process’ is not dependent on 
the presence of IL-7 in our cultures as CD25 and CD127 
expression levels were superimposable in the presence and 
absence of IL-7 (Fig. 4A). Moreover, since a near complete 
reversal between CD25 and CD127 expression has occurred 
by  ∼24-48 h of culture this phenomenon appears in-
dependent of cell division. Numerical T cell expansion does 
not begin in earnest in the cultures until day-3-4 (Fig. 3). 
Interestingly, when expanded T cells were frozen on Day 
14 and subsequently thawed and rested for 24 h in culture 
medium devoid of cytokines, CD127 was re-expressed on 
nearly half of the viable T cells (Fig. 4A). IL-7 receptor 
re-expression could permit delivery of pro-survival signals 
to expanded T cells administered by clinical DLI infusions 
in the lymphopenic post-transplant state where endogenous 
IL-7 level has been demonstrated to be elevated up to 10-30 
pg/mL weeks after transplant [77]. Although it is possible 
that high levels of IL-7 in vivo could induce down-regulation 
of CD127 in the responding T cells, nevertheless our results 
suggest that the expanded T cells retain the capacity to re-ex-
press CD127 even when rested post-thaw with IL-7 at 15-30 
pg/mL (data not shown).
  CD3/CD28 co-stimulation with ClinExVivo
TM Dynabeads
Ⓡ Korean J Hematol 2010;45:224-35.
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in this series of experiments enhanced in a larger fraction 
of post-expansion T cells the capacity for intracellular ex-
pression of IFNγ, TNFα, and Granzyme B than we previously 
reported using different artificial-APC beads [67]. Neverthe-
less, despite the potential for an increase in alloreactivity 
[78] after the more robust expansion in the presence of 
IL-7, the expanded progeny lacked cytotoxicity against a 
highly immunogenic (CD40+, CD80+, CD86+) EBV+ alloge-
neic lymphoblastoid cell line (IM9) (N=7), or recipient fibro-
blasts (N=2), despite a week long pre-sensitization prior to 
performing the CTL assay (Fig. 6). Interestingly, absent cyto-
toxicity coincided with low expression of 4-1BB/CD137, 
CD40L, and perforin. Taken together, these features support 
a favorable safety profile of ‘day 14’ ClinExVivo
TM expanded 
T cells with reduced likelihood for inducing GVHD in vivo 
upon adoptive transfer.
EX VIVO EXPANDED, CD3/CD28-COSTIMULATED 
CORD BLOOD T CELLS CAN BE PRIMED IN VITRO 
AGAINST LYMPHOID AND MYELOID LEUKEMIA
  Donor leukocyte infusion with ‘day 14’ ClinExVivo
TM 
+IL-2 +IL-7 expanded T cells generated from the originally 
infused CB graft could alleviate post-transplant lymphopenia 
and qualitative T cell defects until thymic regeneration could 
contribute new T cells. However, such DLI would be antigen 
non-specific and will require microbial and/or tumor anti-
gens to in vivo prime infused T cells in the transplant 
recipients. In a series of experiments, we evaluated the poten-
tial of ‘day 14’ CD3/CD28-costimulated/expanded T cells 
to undergo in vitro priming against specific leukemic targets. 
In vitro generated tumor-specific CTL responses could be 
adoptively infused to treat leukemia patients with minimal 
residual disease and/or relapse. CD3/CD28-expanded ‘day 
14’ T cells were stimulated in vitro for 3 weeks in parallel 
cultures with killed, Mitomycin C treated lymphoid leukemia 
cells (IM9) and IFNγ-treated myeloid leukemia cells (U937). 
U937 cells by themselves can not induce allogeneic T cell 
response unless a stimulating anti-CD3 antibody is added 
to cultures [79]. In addition, they do not provide co-stim-
ulation via the CD80/CD86-CD28 pathway, but likely via 
the ubiquitously expressed CD147, CD98 molecules [79]. 
CTL priming was performed in the decpreasing presence 
of IL-12, IL7, and IL-15 drawing from our published ex-
perimental strategy to in vitro prime anti-viral responses 
from CB [46]. Robust T cell expansion (195X, ±115, N=4) 
ensued over the course of ∼3 weeks when killed leukemia 
cells rather than ClinExVivo
TM beads served as APC. After 
the course of 2 to 3 repeated stimulations, strong leuke-
mia-specific cytotoxicity was detected in CTL assays, killing 
the stimulating leukemia cells but not the other leukemia 
or most importantly CB transplant recipient PHA blasts (N=4, 
P＜0.01). (Fig. 7). Failure to recognize and kill CB transplant 
recipient PHA blasts indicates future clinical safety from 
the potential toxicity of GVHD.
CONCLUSION
  UCBT is a life-saving form of HCT, however, it is limited 
by the high incidence of OI, most of which are viral. OI 
is the major cause of transplant related mortality during 
the first 6 months after UCBT, and is caused by delays in 
immune reconstitution. For several months, until recovery 
of the thymus is restored to support de novo T cell generation, 
protective antiviral immunity depends on the activity of 
post-thymic T cells that are infused within the CB grafts. 
However, almost all CB T cells are antigen inexperienced 
(naïve) lymphocytes that have been functionally altered by 
placental factors to protect pregnancy. CB T cells need to 
undergo in vivo priming, Th1/Tc1 maturation, and peripheral 
expansion before they can afford immunologic protection. 
Despite advances in our understanding of cellular immune 
recovery after UCBT, fundamental gaps in knowledge remain 
regarding the biology and kinetics of developing anti-
gen-specific protective immunity and understanding the im-
pact of recipient age. However, there is also realistic hope 
that novel immunotherapy strategies could enhance immune 
competence to reduce infectious morbidity, relapse, and im-
prove survival after CBT.
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